News
CMMB
1.680
+3.70%
0.060
Weekly Report: what happened at CMMB last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at CMMB last week (1202-1206)?
Weekly Report · 12/09 11:31
Chemomab Therapeutics to Present at Oppenheimer's Movers in Rare Disease Summit on December 12, 2024
Barchart · 12/03 16:16
Weekly Report: what happened at CMMB last week (1125-1129)?
Weekly Report · 12/02 11:31
Weekly Report: what happened at CMMB last week (1118-1122)?
Weekly Report · 11/25 11:22
Chemomab Therapeutics Reports Positive Phase 2 SPRING Trial Results for CM-101 in Primary Sclerosing Cholangitis
Barchart · 11/19 16:16
Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024
TipRanks · 11/19 12:15
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Barchart · 11/19 06:00
Chemomab Therapeutics Aligns Leadership Incentives with Shareholders
TipRanks · 11/18 21:50
Weekly Report: what happened at CMMB last week (1111-1115)?
Weekly Report · 11/18 11:19
Chemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy Rating
TipRanks · 11/15 19:55
Chemomab Therapeutics Price Target Cut to $11.00/Share From $13.00 by Oppenheimer
Dow Jones · 11/15 16:05
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11
Benzinga · 11/15 15:54
Roth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)
TipRanks · 11/15 13:45
Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05
Seeking Alpha · 11/14 15:00
Chemomab’s Positive Trial Results Boost Investor Confidence
TipRanks · 11/14 12:25
Chemomab Therapeutics sees cash runway through beginning of 2026
TipRanks · 11/14 12:11
Chemomab Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.01) Estimate
Benzinga · 11/14 12:07
CHEMOMAB THERAPEUTICS LTD : QTRLY SHR LOSS $0.01
Reuters · 11/14 12:00
Earnings Scheduled For November 14, 2024
Benzinga · 11/14 08:32
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.